Stem cell therapy for heart failure

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The last decade has witnessed the publication of a large number of clinical trials, primarily using bone marrow-derived stem cells as the injected cell. Much has been learned through these "first-generation" clinical trials. The considerable advances in our understanding include (1) cell therapy is safe, (2) cell therapy has been modestly effective, (3) the recognition that in humans bone marrow-derived stem cells do not transdifferentiate into cardiomyocytes or new blood vessels (or at least in sufficient numbers to have any effect). The primary mechanism of action for cell therapy is now believed to be through paracrine effects that include the release of cytokines, chemokines, and growth factors that inhibit apoptosis and fibrosis, enhance contractility, and activate endogenous regenerative mechanisms through endogenous circulating or site-specific stem cells. The new direction for clinical trials includes the use of stem cells capable of cardiac lineage, such as endogenous cardiac stem cells.

Original languageEnglish (US)
Pages (from-to)105-116
Number of pages12
JournalCardiology in Review
Volume22
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Cell- and Tissue-Based Therapy
Stem Cells
Heart Failure
Clinical Trials
Bone Marrow
Chemokines
Cardiac Myocytes
Blood Vessels
Publications
Intercellular Signaling Peptides and Proteins
Fibrosis
Apoptosis
Cytokines

Keywords

  • bone marrow mononuclear cells
  • cardiac stem cells
  • clinical trials
  • endothelial progenitor cells
  • heart Failure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Stem cell therapy for heart failure. / Michler, Robert E.

In: Cardiology in Review, Vol. 22, No. 3, 2014, p. 105-116.

Research output: Contribution to journalArticle

@article{0de98a1054ad4585bae6e5361cee5145,
title = "Stem cell therapy for heart failure",
abstract = "The last decade has witnessed the publication of a large number of clinical trials, primarily using bone marrow-derived stem cells as the injected cell. Much has been learned through these {"}first-generation{"} clinical trials. The considerable advances in our understanding include (1) cell therapy is safe, (2) cell therapy has been modestly effective, (3) the recognition that in humans bone marrow-derived stem cells do not transdifferentiate into cardiomyocytes or new blood vessels (or at least in sufficient numbers to have any effect). The primary mechanism of action for cell therapy is now believed to be through paracrine effects that include the release of cytokines, chemokines, and growth factors that inhibit apoptosis and fibrosis, enhance contractility, and activate endogenous regenerative mechanisms through endogenous circulating or site-specific stem cells. The new direction for clinical trials includes the use of stem cells capable of cardiac lineage, such as endogenous cardiac stem cells.",
keywords = "bone marrow mononuclear cells, cardiac stem cells, clinical trials, endothelial progenitor cells, heart Failure",
author = "Michler, {Robert E.}",
year = "2014",
doi = "10.1097/CRD.0000000000000018",
language = "English (US)",
volume = "22",
pages = "105--116",
journal = "Cardiology in Review",
issn = "1061-5377",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Stem cell therapy for heart failure

AU - Michler, Robert E.

PY - 2014

Y1 - 2014

N2 - The last decade has witnessed the publication of a large number of clinical trials, primarily using bone marrow-derived stem cells as the injected cell. Much has been learned through these "first-generation" clinical trials. The considerable advances in our understanding include (1) cell therapy is safe, (2) cell therapy has been modestly effective, (3) the recognition that in humans bone marrow-derived stem cells do not transdifferentiate into cardiomyocytes or new blood vessels (or at least in sufficient numbers to have any effect). The primary mechanism of action for cell therapy is now believed to be through paracrine effects that include the release of cytokines, chemokines, and growth factors that inhibit apoptosis and fibrosis, enhance contractility, and activate endogenous regenerative mechanisms through endogenous circulating or site-specific stem cells. The new direction for clinical trials includes the use of stem cells capable of cardiac lineage, such as endogenous cardiac stem cells.

AB - The last decade has witnessed the publication of a large number of clinical trials, primarily using bone marrow-derived stem cells as the injected cell. Much has been learned through these "first-generation" clinical trials. The considerable advances in our understanding include (1) cell therapy is safe, (2) cell therapy has been modestly effective, (3) the recognition that in humans bone marrow-derived stem cells do not transdifferentiate into cardiomyocytes or new blood vessels (or at least in sufficient numbers to have any effect). The primary mechanism of action for cell therapy is now believed to be through paracrine effects that include the release of cytokines, chemokines, and growth factors that inhibit apoptosis and fibrosis, enhance contractility, and activate endogenous regenerative mechanisms through endogenous circulating or site-specific stem cells. The new direction for clinical trials includes the use of stem cells capable of cardiac lineage, such as endogenous cardiac stem cells.

KW - bone marrow mononuclear cells

KW - cardiac stem cells

KW - clinical trials

KW - endothelial progenitor cells

KW - heart Failure

UR - http://www.scopus.com/inward/record.url?scp=84898599924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898599924&partnerID=8YFLogxK

U2 - 10.1097/CRD.0000000000000018

DO - 10.1097/CRD.0000000000000018

M3 - Article

C2 - 24595173

AN - SCOPUS:84898599924

VL - 22

SP - 105

EP - 116

JO - Cardiology in Review

JF - Cardiology in Review

SN - 1061-5377

IS - 3

ER -